Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Clinical trial NCT06850090 · RECRUITING
Trial details
- NCT number
- NCT06850090
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-30
- Primary completion
- 2027-06-01
- Enrollment
- 210
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.